MedPath

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Not Applicable
Recruiting
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Invasive Breast Carcinoma
Prognostic Stage II Breast Cancer AJCC v8
Interventions
Other: Decision Aid
Other: Questionnaire Administration
Registration Number
NCT02918474
Lead Sponsor
M.D. Anderson Cancer Center
Brief Summary

This trial studies the acceptability and how well decision making tool works in supporting decision making in contralateral prophylactic mastectomy in patients with newly diagnosed breast cancer. Decision making tool may help patients with early stage breast cancer make decisions regarding their surgical options.

Detailed Description

PRIMARY OBJECTIVES:

I. An online decision support tool will be field tested that provides patients facing a decision about contralateral prophylactic breast cancer (CPM) with evidence-based information about the expected incidence of contralateral breast cancer and the life expectancy benefit of CPM. The tool will be designed for use in clinical settings and viewed jointly by the patient and physician as part of a shared decision making process around CPM.

OUTLINE:

Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
15
Inclusion Criteria
  • Newly diagnosed ductal breast carcinoma in situ (DCIS) or stage I-III sporadic unilateral invasive breast cancer
  • Able to speak read or write English
Exclusion Criteria
  • Patients with previous breast cancer
  • Prior history of bilateral prophylactic mastectomy
  • Known to have a germline mutation that predisposes them to an increased risk of breast cancer (e.g. BRCA1/2) and/or they are considered at high risk for contralateral breast cancer on the basis of a strong family history of cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Supportive care (decision making tool)Decision AidPatients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
Supportive care (decision making tool)Questionnaire AdministrationPatients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
Primary Outcome Measures
NameTimeMethod
Acceptability of the decision support toolUp to 2 years

Patients' rating of the acceptability of the decision support tool will be assessed using questions from the Ottawa Acceptability Measures, including the clarity, amount, and balance of the information provided by the tool. Acceptability data from patients enrolled in the field test will be reported descriptively.

Changes in patient's knowledge of contralateral prophylactic mastectomy (CPM)Baseline up to 2 years

Will test for change in knowledge from before to after administration of the decision support tool with a breast cancer surgeon using paired samples t-tests.

Reductions in decisional conflict about CPMBaseline up to 2 years

Will be assessed using the Decisional Conflict Scale. Will test for reduction in decisional conflict from before to after administration of the decision support tool with a breast cancer surgeon using paired samples t-tests.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

M D Anderson Cancer Center

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath